| Hang Seng China Enterprises | 86.080 HKD | -0.020 | -0.023% | 223.78M | 19.48B | 89.378 (-3.690%) HKD as at 2025/02/27 | | |
| Hang Seng Index | 23.220 HKD | +0.060 | +0.259% | 826.66M | 19.35B | 23.167 (+0.230%) HKD as at 2025/02/28 | | |
| Hang Seng TECH Index | 5.405 HKD | -0.020 | -0.369% | 1.65B | 9.02B | 5.452 (-0.860%) HKD as at 2025/02/28 | | |
+2x Leveraged Products typically aim to deliver a daily return equivalent to a multiple of the underlying index return that they track. Leveraged Products seeking SFC authorisation shall be subject to a maximum leverage factor of two times (2x). | Hang Seng TECH Index | 6.130 HKD | -0.055 | -0.889% | 385.26M | 2.41B | 6.251 (-1.933%) HKD as at 2025/02/28 | | |
-2x Inverse Products typically aim to deliver the opposite of the daily return of the underlying index that they track. Inverse Products seeking SFC authorisation shall be subject to a maximum leverage factor of one time (-1x); Inverse Products cannot be leveraged. | Hang Seng TECH Index | 1.920 HKD | +0.022 | +1.159% | 1.03B | 1.94B | 1.891 (+1.555%) HKD as at 2025/02/28 | | |
-2x Inverse Products typically aim to deliver the opposite of the daily return of the underlying index that they track. Inverse Products seeking SFC authorisation shall be subject to a maximum leverage factor of one time (-1x); Inverse Products cannot be leveraged. | Hang Seng Index | 2.718 HKD | -0.018 | -0.658% | 258.84M | 694.69M | 2.720 (-0.088%) HKD as at 2025/02/28 | | |
+2x Leveraged Products typically aim to deliver a daily return equivalent to a multiple of the underlying index return that they track. Leveraged Products seeking SFC authorisation shall be subject to a maximum leverage factor of two times (2x). | Hang Seng Index | 4.972 HKD | +0.034 | +0.689% | 94.33M | 475.01M | 4.972 (+0.010%) HKD as at 2025/02/28 | | |
| Hang Seng TECH Index | 11.550 HKD | -0.090 | -0.773% | 36.76M | 427.77M | 12.324 (-6.280%) HKD as at 2025/02/27 | | |
| Hang Seng TECH Index | 6.990 HKD | -0.030 | -0.427% | 42.35M | 299.23M | 7.053 (-0.899%) HKD as at 2025/02/28 | | |
| Hang Seng TECH Index | 5.490 HKD | -0.015 | -0.272% | 40.62M | 225.69M | 5.839 (-5.977%) HKD as at 2025/02/27 | | |
| FTSE 3-Month US Dollar Eurodeposit Index | 116.950 USD | +0.150 | +0.128% | 1.62M | 189.43M | 116.816 (+0.115%) USD as at 2025/02/28 | | |
| HSI ESG Enhanced Index (net total return index) | 47.540 HKD | +0.100 | +0.211% | 3.62M | 171.79M | 47.552 (-0.026%) HKD as at 2025/02/28 | | |
| London Gold Fixing Price | 2,051.000 HKD | +1.000 | +0.049% | 73.48K | 150.89M | N/A | | |
+2x Leveraged Products typically aim to deliver a daily return equivalent to a multiple of the underlying index return that they track. Leveraged Products seeking SFC authorisation shall be subject to a maximum leverage factor of two times (2x). | Solactive Gold 1-Day Rolling Futures Index | 13.110 HKD | -0.020 | -0.152% | 7.75M | 101.81M | 13.347 (-1.774%) HKD as at 2025/02/27 | | |
| CSI 300 | 27.580 HKD | -0.040 | -0.145% | 3.54M | 98.58M | 28.163 (-2.070%) HKD as at 2025/02/27 | | |
| CME CF Bitcoin Reference Rate- Asia Pacific Variant | 11.360 HKD | +1.660 | +17.113% | 7.51M | 85.80M | 9.784 (+16.103%) HKD as at 2025/02/28 | | |
| FTSE China A50 | 13.500 HKD | -0.010 | -0.074% | 5.88M | 79.45M | 13.692 (-1.403%) HKD as at 2025/02/27 | | |
| Hang Seng High Dividend Yield | 24.400 HKD | +0.020 | +0.082% | 2.85M | 69.82M | 25.005 (-2.418%) HKD as at 2025/02/27 | | |
| CSI 300 | 42.760 HKD | -0.060 | -0.140% | 1.60M | 68.57M | 43.861 (-2.510%) HKD as at 2025/02/27 | | |
+2x Leveraged Products typically aim to deliver a daily return equivalent to a multiple of the underlying index return that they track. Leveraged Products seeking SFC authorisation shall be subject to a maximum leverage factor of two times (2x). | Hang Seng China Enterprises | 3.200 HKD | +0.008 | +0.251% | 18.48M | 60.07M | 3.215 (-0.476%) HKD as at 2025/02/28 | | |
| FTSE China A50 | 12.600 HKD | 0.000 | 0.000% | 3.17M | 40.00M | 12.640 (-0.320%) HKD as at 2025/02/28 | | |
-2x Inverse Products typically aim to deliver the opposite of the daily return of the underlying index that they track. Inverse Products seeking SFC authorisation shall be subject to a maximum leverage factor of one time (-1x); Inverse Products cannot be leveraged. | Hang Seng China Enterprises | 2.040 HKD | 0.000 | 0.000% | 18.90M | 37.83M | 2.033 (+0.334%) HKD as at 2025/02/28 | | |
-2x Inverse Products typically aim to deliver the opposite of the daily return of the underlying index that they track. Inverse Products seeking SFC authorisation shall be subject to a maximum leverage factor of one time (-1x); Inverse Products cannot be leveraged. | NASDAQ-100 Index | 5.130 HKD | -0.170 | -3.208% | 7.00M | 35.91M | 5.307 (-3.335%) HKD as at 2025/02/27 | | |
| SSE Science and Technology Innovation Board 50 Index | 9.555 HKD | -0.215 | -2.201% | 3.66M | 35.36M | 10.221 (-6.519%) HKD as at 2025/02/27 | | |
| Hang Seng China Enterprises | 10.470 HKD | +0.090 | +0.867% | 2.69M | 28.23M | 10.732 (-2.445%) HKD as at 2025/02/27 | | |
| CME Bitcoin Futures | 32.240 HKD | +4.680 | +16.981% | 635.41K | 20.55M | 29.163 (+10.552%) HKD as at 2025/02/27 | | |
+2x Leveraged Products typically aim to deliver a daily return equivalent to a multiple of the underlying index return that they track. Leveraged Products seeking SFC authorisation shall be subject to a maximum leverage factor of two times (2x). | CSI 300 | 3.630 HKD | -0.014 | -0.384% | 3.80M | 13.90M | 3.824 (-5.073%) HKD as at 2025/02/27 | | |
| CSI 300 | 40.200 CNY | -0.020 | -0.050% | 330.23K | 13.30M | 41.036 (-2.038%) CNY as at 2025/02/27 | | |
+2x Leveraged Products typically aim to deliver a daily return equivalent to a multiple of the underlying index return that they track. Leveraged Products seeking SFC authorisation shall be subject to a maximum leverage factor of two times (2x). | ChiNext Index (HKD)(CNH) | 3.942 HKD | +0.080 | +2.071% | 3.34M | 13.22M | 3.870 (+1.853%) HKD as at 2025/02/28 | | |
| Hang Seng Hong Kong-Listed Biotech Index | 10.100 HKD | -0.070 | -0.688% | 1.27M | 12.93M | 10.241 (-1.376%) HKD as at 2025/02/28 | | |